Johnson & Johnson
Johnson & Johnson’s Stelara receives FDA approval
September 27, 2016Manufacturing and Production, Research and Development Janssen Biotech, Johnson & Johnson, Stelara
The drug is approved for use to treat the skin condition scaly plaque psoriasis and a type of arthritis associated …
J&J in $4.33bn eye surgery unit acquisition
September 19, 2016Manufacturing and Production, Sales and Marketing Abbott, Johnson & Johnson, acquisition
Johnson & Johnson has agreed to buy Abbott Laboratories’ eye surgery equipment unit in an all-cash deal for £4.33 billion …
GSK and J&J file rheumatoid arthritis treatment sirukumab in EU
September 13, 2016Manufacturing and Production, Sales and Marketing GSK, GlaxoSmithKline, Johnson & Johnson, rheumatoid arthritis, sarilumab, sirukumab
GlaxoSmithKline and partner Johnson & Johnson’s Janssen Biologics unit have filed for approval of rheumatoid arthritis (RA) treatment sirukumab in …
Janssen’s New Drug Application for drug to treat intestinal worms gets US FDA priority review
July 14, 2016Manufacturing and Production, Research and Development, Sales and Marketing Johnson & Johnson, US FDA, WHO, drug trial, new drug application, regulation, soil-transmitted helminthiasis
Johnson & Johnson (NYSE: JNJ) said the US Food and Drug Administration (FDA) has granted Priority Review for its New …
J&J raises FY outlook, Q1 beats estimates
April 20, 2016Business Services, Research and Development, Sales and Marketing Financial, Johnson & Johnson, Q1, earnings, results, revenue, sales
Healthcare giant Johnson & Johnson (NYSE: JNJ) raised its full-year outlook and posted first-quarter earnings ahead of estimates despite currency headwinds. …
Janssen slams NICE decision on Imbruvica
March 2, 2016Research and Development, Sales and Marketing CLL, Cancer, Cancer Drugs Fund, Janssen, Johnson & Johnson, NICE, imbruvica
Janssen, the R&D arm of pharma major Johnson & Johnson, says it is extremely disappointed following regulator NICE’s announcement that …
J&J fined $72 million in talc cancer case
February 24, 2016Research and Development, Sales and Marketing Johnson & Johnson
A Missouri jury has ruled that Johnson & Johnson must pay $72 million to the family of an Alabama woman, …
Investigation questions Xarelto trial data accuracy
February 4, 2016Medical Communications BMJ, Bayer, INR, Johnson & Johnson, New England Journal of Medicine, Rocket-AF, Xarelto, blood clotting, rivaroxaban
The ROCKET-AF trial, the pivotal trial of the top-selling anti-clotting drug Xarelto, could have been undermined by unreliable results from …
Johnson & Johnson begins Ebola vaccine trial in Sierra Leone
October 14, 2015Research and Development Ebola vaccine, Johnson & Johnson
Johnson & Johnson has begun a safety and immunogenicity clinical trial in Sierra Leone of a preventive Ebola vaccine regimen …
FDA strengthens safety warning for J&J’s diabetes drug Invokana
September 14, 2015Sales and Marketing FDA, Food and Drugs Administration, Invokamet, J&J, JJ, Johnson & Johnson, diabetes, invokana, safety warning, type 2 diabetes
Johnson & Johnson has suffered a blow after the FDA strengthened its safety warning for the company’s type 2 diabetes …
Janssen sales follow J&J’s downward trend
July 15, 2015Sales and Marketing J&J, JJ, Johnson & Johnson, Johnson and Johnson, financial results, olysio
Strong sales of its new hepatitis C treatment Olysio were not enough to stop a slump in profits at J&J’s …
J&J profits down in Q3
October 17, 2012Sales and Marketing J&J, JJ, Johnson & Johnson, Q3, Risperdal
Johnson & Johnson has reported a 6.5% year-on-year sales increase to $17.1 billion in the third quarter of 2012, a …
Pharma creates non-profit R&D organisation
September 21, 2012Research and Development, Sales and Marketing Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Co, GlaxoSmithKline, Johnson & Johnson, Pfizer, R&D, Roche Genentech, Sanofi, TransCelerate BioPharma, biopharma
Ten biopharma companies have formed TransCelerate BioPharma Inc, a not-for-profit organisation using money and personnel from each firm, with a …
J&J buys into Genmab cancer drug
August 31, 2012Sales and Marketing Cancer, Genmab, Janssen Cilag, Janssen-Cilag, Johnson & Johnson, multiple myeloma
Danish biotech company Genmab has sold the worldwide rights for one of its cancer drugs to Johnson & Johnson-owned Janssen …
Sheri McCoy resigns from Johnson & Johnson
April 10, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Johnson & Johnson, Sheri McCoy, resignation
Johnson & Johnson has announced that Sheri McCoy, vice chairman of the executive committee, will leave the company on April …
Latest content
Five Facts about cardiovascular disease
